Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth

References

• Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362:2202 - 11; http://dx.doi.org/10.1056/NEJMra0804577; PMID: 20558371
   PubMed Web of Science ®Google Scholar
• Zage PE, Nolo R, Fang W, Stewart J, Garcia-Manero G, Zweidler-McKay PA. Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatr Blood Cancer 2012; 58:682 - 9; http://dx.doi.org/10.1002/pbc.23202; PMID: 21744479
   PubMed Web of Science ®Google Scholar
• Wojtalla A, Salm F, Christiansen DG, Cremona T, Cwiek P, Shalaby T, Gross N, Grotzer MA, Arcaro A. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS One 2012; 7:e47109; http://dx.doi.org/10.1371/journal.pone.0047109; PMID: 23056595
   PubMed Web of Science ®Google Scholar
• Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 1997; 79:2028 - 35; http://dx.doi.org/10.1002/(SICI)1097-0142(19970515)79:10<2028::AID-CNCR26>3.0.CO;2-V; PMID: 9149032
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol 2003; 41:508 - 15; http://dx.doi.org/10.1002/mpo.10273; PMID: 14595707
   PubMedGoogle Scholar
• Cianfarani S, Rossi P. Neuroblastoma and insulin-like growth factor system. New insights and clinical perspectives. Eur J Pediatr 1997; 156:256 - 61; http://dx.doi.org/10.1007/s004310050595; PMID: 9128806
   PubMed Web of Science ®Google Scholar
• Gilbertson R. Paediatric embryonic brain tumours. biological and clinical relevance of molecular genetic abnormalities. Eur J Cancer 2002; 38:675 - 85; http://dx.doi.org/10.1016/S0959-8049(01)00315-X; PMID: 11916550
   PubMed Web of Science ®Google Scholar
• Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002; 62:6462 - 6; PMID: 12438236
   PubMed Web of Science ®Google Scholar
• Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like growth factor system and sarcomas. J Pathol 2009; 217:469 - 82; http://dx.doi.org/10.1002/path.2499; PMID: 19148905
   PubMed Web of Science ®Google Scholar
• Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001; 24:385 - 428; http://dx.doi.org/10.1146/annurev.neuro.24.1.385; PMID: 11283316
   PubMed Web of Science ®Google Scholar
• Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17:615 - 75; http://dx.doi.org/10.1146/annurev.cellbio.17.1.615; PMID: 11687500
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010; 11:329 - 41; http://dx.doi.org/10.1038/nrm2882; PMID: 20379207
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Vogt PK, Rommel C. PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol 2010; 347:1 - 19; http://dx.doi.org/10.1007/82_2010_65; PMID: 20549473
   PubMed Web of Science ®Google Scholar
• Carter Y, Jaskula-Sztul R, Chen H, Mazeh H. Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch. Neuroendocrinology 2013; 97:57 - 66; http://dx.doi.org/10.1159/000335136; PMID: 22343668
   PubMed Web of Science ®Google Scholar
• Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 2009; 273:194 - 200; http://dx.doi.org/10.1016/j.canlet.2008.05.045; PMID: 18606491
   PubMed Web of Science ®Google Scholar
• Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med Res Rev 2008; 28:773 - 96; http://dx.doi.org/10.1002/med.20119; PMID: 18271054
   PubMed Web of Science ®Google Scholar
• Dickey A, Schleicher S, Leahy K, Hu R, Hallahan D, Thotala DK. GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line. J Neurooncol 2011; 104:145 - 53; http://dx.doi.org/10.1007/s11060-010-0491-3; PMID: 21161565
   PubMed Web of Science ®Google Scholar
• Pizarro JG, Folch J, Esparza JL, Jordan J, Pallàs M, Camins A. A molecular study of pathways involved in the inhibition of cell proliferation in neuroblastoma B65 cells by the GSK-3 inhibitors lithium and SB-415286. J Cell Mol Med 2009; 13:9B 3906 - 17; http://dx.doi.org/10.1111/j.1582-4934.2008.00389.x; PMID: 18624766
   PubMed Web of Science ®Google Scholar
• Ngok-Ngam P, Watcharasit P, Thiantanawat A, Satayavivad J. Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Bax oligomerization in neuroblastoma SH-SY5Y cells. Cell Mol Biol Lett 2013; 18:58 - 74; http://dx.doi.org/10.2478/s11658-012-0039-y; PMID: 23161404
   PubMed Web of Science ®Google Scholar
• Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005; 65:2076 - 81; http://dx.doi.org/10.1158/0008-5472.CAN-04-3642; PMID: 15781615
   PubMed Web of Science ®Google Scholar
• Wilson W 3rd, Baldwin AS. Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res 2008; 68:8156 - 63; http://dx.doi.org/10.1158/0008-5472.CAN-08-1061; PMID: 18829575
   PubMed Web of Science ®Google Scholar
• Pinchot SN, Adler JT, Luo Y, Ju J, Li W, Shen B, Kunnimalaiyaan M, Chen H. Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. Am J Surg 2009; 197:313 - 9; http://dx.doi.org/10.1016/j.amjsurg.2008.10.007; PMID: 19245907
   PubMed Web of Science ®Google Scholar
• Adler JT, Cook M, Luo Y, Pitt SC, Ju J, Li W, Shen B, Kunnimalaiyaan M, Chen H. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol Cancer Ther 2009; 8:914 - 20; http://dx.doi.org/10.1158/1535-7163.MCT-08-0712; PMID: 19372564
   PubMed Web of Science ®Google Scholar
• Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 2007; 6:1151 - 8; http://dx.doi.org/10.1158/1535-7163.MCT-06-0665; PMID: 17363508
   PubMed Web of Science ®Google Scholar
• Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O’Neill S, Mazzocco K, Roberts P, Nicholson J, Ellershaw C, et al, United Kingdom Children Cancer Study Group and the United Kingdom Cancer Cytogenetics Group. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 2001; 19:3080 - 90; PMID: 11408505
   PubMed Web of Science ®Google Scholar
• Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004; 3:479 - 87; http://dx.doi.org/10.1038/nrd1415; PMID: 15173837
   PubMed Web of Science ®Google Scholar
• Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 1993; 12:803 - 8; PMID: 8382613
   PubMed Web of Science ®Google Scholar
• Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem 2006; 281:39819 - 30; http://dx.doi.org/10.1074/jbc.M603578200; PMID: 17090547
   PubMed Web of Science ®Google Scholar
• Greenblatt DY, Cayo MA, Adler JT, Ning L, Haymart MR, Kunnimalaiyaan M, Chen H. Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg 2008; 247:1036 - 40; http://dx.doi.org/10.1097/SLA.0b013e3181758d0e; PMID: 18520232
   PubMed Web of Science ®Google Scholar